ORALE SUSPENSION VON TEMOZOLOMID

European patent · EP3613436 · In force

Register entry

Publication number
EP3613436
Application number
EP18306683
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 13, 2018
Published
Feb 26, 2020
Granted
Jun 2, 2021
Protection ends at the latest
Dec 12, 2038
Next annual fee due
Dec 31, 2026
IPC classes
A61K 47/02 (2006.01)
A61K 47/10 (2017.01)
A61K 47/12 (2006.01)
A61K 9/00 (2006.01)
A61K 47/32 (2006.01)
A61K 47/36 (2006.01)
A61K 47/38 (2006.01)
A61K 47/40 (2006.01)
A61K 31/495 (2006.01)
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Jan 1, 2025

    Change

    Published in Swissreg on 01.01.2025

  3. Jan 1, 2024

    Change

    Published in Swissreg on 01.01.2024

  4. Jan 1, 2023

    Change

    Published in Swissreg on 01.01.2023

  5. Apr 13, 2022

    Change

    Published in Swissreg on 13.04.2022

  6. Jun 2, 2021

    Granted

    Published in Swissreg on 02.06.2021

Parties

Holder

Institut Gustave Roussy

39, rue Camille Desmoulins, 94805 Villejuif Cédex, FR

Orphelia Pharma

85 Bd St Michel, 75005 Paris, FR

Inventor

BIENAYME, Hugues

69360 Saint Symphorien d'Ozon, FR

BASTID, Jérémy

69160 Tassin la Demi Lune, FR

SCHMITT, Mathieu

75017 Paris, FR

ANNEREAU, Maxime

94300 Vincennes, FR

LEMARE, François

92150 Suresnes, FR

TORTOLANO, Lionel

75011 Paris, FR

ABBOU, Samuel

75013 Paris, FR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.